<?xml version='1.0' encoding='utf-8'?>
<document id="29488691"><sentence text="Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer."><entity charOffset="56-64" id="DDI-PubMed.29488691.s1.e0" text="rifampin" /></sentence><sentence text="The CFTR potentiator ivacaftor is responsible for significant clinical improvements among a subset of patients with cystic fibrosis" /><sentence text=" Because it is a substrate of the cytochrome P450 system, specifically CYP3A4/5, ivacaftor is subject to significant drug-drug interactions, including due to commonly used antimicrobials such as rifampin"><entity charOffset="195-203" id="DDI-PubMed.29488691.s3.e0" text="rifampin" /></sentence><sentence text=" While the interaction of rifampin and ivacaftor has been examined in vitro, severe adverse events resulting from this interaction have not been reported in the literature"><entity charOffset="26-34" id="DDI-PubMed.29488691.s4.e0" text="rifampin" /><entity charOffset="39-48" id="DDI-PubMed.29488691.s4.e1" text="ivacaftor" /><pair ddi="false" e1="DDI-PubMed.29488691.s4.e0" e2="DDI-PubMed.29488691.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29488691.s4.e0" e2="DDI-PubMed.29488691.s4.e1" /></sentence><sentence text=" In this report, we describe the termination of steady, long-term improvement in a patient taking ivacaftor, resulting from the use of rifampin and precipitating a significant pulmonary exacerbation"><entity charOffset="135-143" id="DDI-PubMed.29488691.s5.e0" text="rifampin" /></sentence><sentence text="" /></document>